Anika Therapeutics (ANIK) Tops Q2 EPS by 38c ; Offers Guidance

Anika Therapeutics (NASDAQ: ANIK) reported Q2 EPS of $0.06, $0.38 better than the analyst estimate of ($0.32). Revenue for the quarter came in at $44.3 million versus the consensus estimate of $40.37 million.

GUIDANCE:

Anika Therapeutics sees FY2023 revenue of $159.5-163 million, versus the consensus of $161.9 million.

For earnings history and earnings-related data on Anika Therapeutics (ANIK) click here.

You May Also Be Interested In

• BofA raises AMD target to $720, sees server CPU TAM tripling to $211B by 2030
• Paychex (PAYX) Tops Q1 EPS by 2c
• MVB Bank partners with DingoBlu on mobile banking platform